Gender Male
Huaixiang Hao is co-founder and Senior Director of Biology at PAQ Therapeutics. He brings over a decade of research and clinical trial experience from his time as a postdoctoral fellow, investigator and principal scientist of Oncology at the Novartis Institutes for BioMedical Research. Dr. Hao’s expertise lies in his extensive knowledge of targeted
therapies and biomarker and combination strategies, which has led him to author 26 publications and file eight patents in his field. His research in cellular pharmacology has accelerated the drug discovery and development of SHP2 inhibitors and led to the identification of several predictive biomarkers for mTOR inhibitors and Wnt signaling inhibitors. Dr. Hao earned his PhD in Biochemistry at the University of Utah.
